The Administration proposed two care models earlier this year to reduce government costs of Part B and D treatments. While both sought to address legitimate fiscal concerns, CLL Society questioned whether the Centers for Medicare and Medicaid Services (CMS) had the authority to undertake such models as well as the government’s ability to maintain beneficiary access and care quality. Under the model proposed for Part D drugs (oral or self-injected treatments), CLL Society pointed to likely health plan actions like higher premiums, tighter formularies, or increased cost-sharing. Under the Part B model (for treatments administered by a clinician), CLL Society expressed concern about creating instability for providers, causing shifts in site-of-care, which are particularly concerning where specialized infusion protocols, clinical trial participation, and multidisciplinary care are concerned. Read the letters here.
